Oncolys BioPharma Management
Management criteria checks 1/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Key information
Yasuo Urata
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 20.1yrs |
CEO ownership | 2.4% |
Management average tenure | no data |
Board average tenure | 9.1yrs |
Recent management updates
CEO
Yasuo Urata (68 yo)
20.1yrs
Tenure
Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT P...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Representative Director | 20.1yrs | no data | 2.45% ¥ 348.8m | |
Director of Finance & Accounting | 11.1yrs | no data | 0.089% ¥ 12.6m | |
External Auditor | 12.6yrs | no data | 0.0049% ¥ 702.2k | |
In Charge of CMC Planning and Overseas Leader & Director | 16.1yrs | no data | 0.57% ¥ 80.7m | |
Corporate Auditor | 7.1yrs | no data | 0.0020% ¥ 280.6k | |
Independent External Director | 2.1yrs | no data | no data | |
Outside Auditor | 3.1yrs | no data | no data | |
Independent Outside Director | 1.1yrs | no data | no data |
9.1yrs
Average Tenure
67yo
Average Age
Erfahrener Vorstand: 4588Die Vorstandsmitglieder gelten als erfahren (8.8 Jahre durchschnittliche Amtszeit).